Prelude Therapeutics and QDX use quantum chemistry to develop mutant-selective JAK2 inhibitors for blood cancers, with Incyte acquiring the …
Prelude Therapeutics and QDX use quantum chemistry to develop mutant-selective JAK2 inhibitors for blood cancers, with Incyte acquiring the …